Ratings by Chardan (Daniil Gataulin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/9/2026 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2026 | EyePoint Inc. | EYPT | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2025 | Kalaris | KLRS | New Coverage | Buy (N/A) |
9.13 (4.38) |
-52.03% | Details | |
| 12/23/2025 | Annexon Biosciences | ANNX | New Coverage | Buy (N/A) |
5.17 (5.80) |
12.19% | Details | |
| 10/27/2025 | Adverum Biotechnologies | ADVM | Downgrade | Neutral (Buy) |
4.18 (4.36) |
4.31% | Details | |
| 10/16/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
2.00 (3.27) |
63.5% | Details | |
| 9/15/2025 | Ocular Therapeutix | OCUL | New Coverage | Buy (N/A) |
12.81 (8.97) |
-29.98% | Details | |
| 9/9/2025 | Tourmaline Bio | TRML | Downgrade | Neutral (Buy) |
30.18 (47.98) |
58.98% | Details | |
| 7/18/2025 | Clearside Biomedical | CLSD | Downgrade | Neutral (Buy) |
0.84 (0.41) |
-51.19% | Details | |
| 4/23/2025 | Tourmaline Bio | TRML | New Coverage | Buy (N/A) |
16.76 (30.18) |
80.07% | Details | |
| 4/1/2025 | uniQure BV | QURE | New Coverage | Buy (N/A) |
10.60 (40.25) |
279.72% | Details | |
| 3/26/2025 | Zura Bio Ltd. | ZURA | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2025 | Unity Biotechnology Inc | UBX | New Coverage | Buy (N/A) |
1.33 (0.20) |
-84.96% | Details | |
| 12/2/2024 | Outlook Therapeutics Incs. | OTLK | Downgrade | Neutral (Buy) |
1.70 (1.39) |
-18.24% | Details | |
| 8/21/2024 | Clearside Biomedical | CLSD | New Coverage | Buy (N/A) |
1.00 (0.84) |
-16% | Details | |
| 8/14/2024 | Zura Bio Ltd. | ZURA | New Coverage | Buy (N/A) |
3.29 (5.45) |
65.65% | Details | |
| 7/31/2024 | MeiraGTx Holdings plc | MGTX | New Coverage | Buy (N/A) |
4.92 (12.44) |
152.85% | Details | |
| 6/7/2024 | Cognition Therapeutics | CGTX | New Coverage | Buy (N/A) |
1.90 (0.96) |
-49.47% | Details | |
| 2/15/2024 | Outlook Therapeutics Incs. | OTLK | Upgrade | Buy (Neutral) |
0.42 (1.70) |
304.76% | Details | |
| 10/31/2023 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
0.50 (48.86) |
9672% | Details | |
| 8/31/2023 | Outlook Therapeutics Incs. | OTLK | Downgrade | Neutral (Buy) |
0.27 (1.39) |
414.81% | Details | |
| 9/13/2022 | Outlook Therapeutics Incs. | OTLK | New Coverage | Buy (N/A) |
1.12 (1.39) |
24.11% | Details | |
| 7/7/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Buy (N/A) |
7.79 (13.30) |
70.73% | Details |
